Pricing Sign in

TRDA

Entrada Therapeutics, Inc.distress 2/10 · well-funded / low risk

$6.08-1%today-62% from 52w high

entradatx.com152 employeesFounded 2016Boston, MABiotechnology

Lead: Duchenne muscular dystrophy · est. market ~$4B (approx, global)

Revenue

pre-revenue

Liquidity

$239M

Runway

1.8 yrs

Shares 1y

+2%

Price & events

-48.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.2%

1D

-11.6%

1W

-16.1%

1M

-52.6%

3M

-46.9%

6M

-4.9%

1Y

-64.6%

2Y

—

5Y

-74.6%

All

Overview

Market Cap: $235.84M
Volume: 13.79K
52 Week Range: $5.02 – $16.03
Total Shares: 38.82M
Float Shares: 21.41M
Short %: 8.45%
% Held by Insiders: 12.31%
% Held by Institutions: 78.89%
RVOL: 0.04x
Beta: -0.26

Pipeline stages · 1 programs

ENTR-601-44, ENTR-601-45

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2029-03-01

Pipeline · 3 trials · 3 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2029-03-01 Estimated 50% readout ~2029-04-15	Phase 1/2	ENTR-601-45rare pediatric	Duchenne Muscular Dystrophy (DMD)	—	recruiting
2029-03-28 Estimated 50% readout ~2029-05-12	Phase 1/2	ENTR-601-44rare pediatric	Duchenne Muscular Dystrophy (DMD)	—	recruiting
2032-03 Estimated 50% readout ~2032-04-15	Phase 2	ENTR-601-44, ENTR-601-45rare pediatric	Duchenne Muscular Dystrophy (DMD)	—	not yet recruiting

Catalyst news & presentations · 13

by end of 2026Guided 40%trial initiationsecondaryPhase 1/2ENTR-601-50 · Initiate global Phase 1/2 MAD clinical studySEC 8-K
H2 2026Guided 55%readoutPhase 1/2VX-670 · MAD portion results shared by VertexSEC 8-K
year-end 2026Guided 40%readoutPhase 1/2ENTR-601-44 · Cohort 1 open-label and Cohort 2 MAD dataSEC 8-K
2026Guided 40%regulatory submissionFiled (NDA/BLA)ENTR-601-51 · Regulatory filing for Phase 1/2 clinical studySEC 8-K
2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
mid-2026readoutPhase 1/2ENTR-601-45 · Cohort 1 dataSEC 8-K
first half of 2026trial initiationsecondaryPhase 1ENTR-601-44 · Initiate enrollment for Phase 1b multiple ascending dose study in U.S.SEC 8-K
January 14, 2026conferencedata presentationsecondaryPresent at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
2025regulatory submissionFiled (NDA/BLA)ENTR-601-50 · Regulatory filing for Phase 1/2 clinical studySEC 8-K
H2 2025trial initiationsecondaryPhase 1/2ENTR-601-50 · Initiation of global Phase 1/2 MAD studySEC 8-K
third quarter of 2025trial initiationsecondaryPhase 1/2ENTR-601-45 · Initiate Phase 1/2 MAD clinical study in UKSEC 8-K
second quarter of 2025trial initiationsecondaryPhase 1/2ENTR-601-44 · Phase 1/2 multiple ascending dose clinical study in patients with DMD amenable to exon 44 skipping.SEC 8-K
2025-03-24fda agreementENTR-601-45 · Received authorization from UK MHRA and REC for Phase 1/2 trialSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 38,820,616 · 0 offerings/1y · 0 PIPEs

2025-12-03EFFECTshelf_effective
2025-11-06S-3shelf_registration
2024-11-14SC 13G/Astrategic_stake
2024-06-26SC 13D/Astrategic_stake
2024-06-248-Kmaterial_agreement
2024-06-24424B5offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

no consensus

2026-06-08GuggenheimBuy
2026-05-08HC Wainwright & Co.Buy → Neutral
2026-04-06OppenheimerOutperform
2026-02-18HC Wainwright & Co.Buy
2026-02-11GuggenheimBuy
2025-05-20HC Wainwright & Co.Buy

Competitors — Duchenne muscular dystrophy

EWTXEdgewise Therapeutics, Inc.$4.1B · D4
DYNDyne Therapeutics, Inc.$3.3B · D4
SRPTSarepta Therapeutics, Inc.$1.6B · D2
WVEWave Life Sciences Ltd.$1.1B · D1
CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
SLDBSolid Biosciences Inc.$777M · D4
RGNXREGENXBIO Inc.$508M · D7
DTILPRECISION BIOSCIENCES INC$185M · D6
PEPGPepGen Inc.$133M · D6
CPIXCUMBERLAND PHARMACEUTICALS INC$102M · D0

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.